New mRNA vaccine targets Hard-to-Treat lymphoma
NCT ID NCT07334574
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a personalized mRNA vaccine (XP-006) for people with B-cell non-Hodgkin's lymphoma that has returned or not responded to treatment. The vaccine is custom-made to target each person's tumor. The main goal is to check safety and find the right dose, while also looking at how well it controls the disease. About 20 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
Shanghai, 200020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.